Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of PF-07220060 + PF-07104091 plus endocrine therapy in advanced HR-positive HER2-negative breast cancer and other solid tumors
2022-002173-28Phase 2Active
- Sponsor
- Pfizer
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atirmociclib and tegtociclib in breast cancer and Nonhematologic neoplasms, sponsored by Pfizer. Primary endpoints: Safety and tolerability of PF-07220060 + PF-07104091 plus endocrine therapy (Part 1 dose escalation), Pharmacokinetics of PF-07220060 and PF-07104091 (Part 1 and Part 2) and 2 more. Started Dec 2022; status: active.
02
Drugs
atirmociclibtegtociclib
03
Conditions
breast cancerNonhematologic neoplasms
Beyond the preview
Go deeper on 2022-002173-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002173-28.